BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37890739)

  • 1. Targeting the NF-E2-related factor 2 pathway for overcoming leukemia.
    Harifi-Mood MS; Daroudi M; Darroudi M; Naseri K; Samarghandian S; Farkhondeh T
    Int J Biol Macromol; 2023 Dec; 253(Pt 8):127594. PubMed ID: 37890739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
    Xue D; Zhou X; Qiu J
    Biomed Pharmacother; 2020 Nov; 131():110676. PubMed ID: 32858502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
    Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
    Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of the Nrf2-Keap1 signaling pathway in cancer.
    Jaramillo MC; Zhang DD
    Genes Dev; 2013 Oct; 27(20):2179-91. PubMed ID: 24142871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.
    Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M
    J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs.
    Telkoparan-Akillilar P; Suzen S; Saso L
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
    Rushworth SA; Bowles KM; MacEwan DJ
    Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma.
    Tian B; Lu ZN; Guo XL
    Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
    Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
    Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
    Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
    Panieri E; Saso L
    Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.
    Zhang J; Su L; Ye Q; Zhang S; Kung H; Jiang F; Jiang G; Miao J; Zhao B
    Oncotarget; 2017 Jan; 8(5):7625-7636. PubMed ID: 28032588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
    Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
    Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.
    Rushworth SA; Zaitseva L; Murray MY; Shah NM; Bowles KM; MacEwan DJ
    Blood; 2012 Dec; 120(26):5188-98. PubMed ID: 23077289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.
    Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Mäkinen A; Laukkanen S; Mäkinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lönnberg T; Lohi O; Heinäniemi M
    Genome Med; 2020 Nov; 12(1):99. PubMed ID: 33218352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
    Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
    J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.